NEW YORK, April 16, 2013 /PRNewswire/ -- Exosome Diagnostics, a developer of biofluid-based molecular diagnostic products for use in personalized medicine, today announced data demonstrating exosome technology performance in clinical applications which will be presented at the International Society for Extracellular Vesicles 2013 (ISEV 2013) annual meeting, April 16-20, in Boston. The ISEV meeting is the preeminent international conference in the rapidly growing field of exosome and microvesicle research.
"The ability to deliver full-length, high quality mRNA and microRNA from biofluids is critical to development of new research tools and clinical grade in vitro diagnostic tests not subject to the limitations of tissue biopsy," said Dr. Johan Skog, chief science officer of Exosome Diagnostics. "Our Alzheimer's disease findings are especially pertinent to advancing a molecular diagnostic test capable of detecting CNS disorders years before the onset of clinical symptoms when therapeutic intervention could provide the most benefit."
Dr. Skog will give two oral presentations. The first is entitled "Characterization of Exosome RNA as a Tool for Molecular Diagnostics", and will be given at 9:30 a.m. EDT on April 16 during the Frye Halloran Educational Symposium. The latest data on Exosome Diagnostics' proprietary biofluid RNA capture technology for disease biomarkers in urine, blood and cerebrospinal fluid (CSF) will be presented. The second, to be given at 9:45 a.m. EDT on April 20, is entitled "The Use Of CSF Microvesicle RNA For Diagnosis Of Alzheimer's Disease". This presentation describes differences in CSF exosome microRNA expression associated with Alzheimer's disease and patients with subjective memory complaints but no evidence of Alzheimer's disease.
James McCullough, chief executive officer of Exosome, said, "We are committed to enabling the research community with high-performance exosome technology RNA isolation kits beginning in 2014 for biomarker discovery from fresh and frozen biofluids. In addition, we are continuing to advance multi-center in vitro diagnostic development programs in genitourinary (GU) Oncology and CNS disorders."
Exosome Diagnostics' proprietary technology provides access to a previously unexplored source of genetic information directly from diseased cell populations. Cells throughout the body shed exosomes into fluids as a natural package delivery system to other cells. Exosomes carry key genes (mRNA and miRNA transcript) responsible for commanding disease growth that can be accessed quickly and repeatedly from a biofluid for analysis on PCR or next-generation sequencing instruments. Exosome technology has the potential to allow doctors, researchers and drug developers to take repeated, accurate genetic "snapshots" of disease for diagnostic and therapeutic use without the need for a surgical tissue biopsy.
Exosome Diagnostics will also be presenting a poster on an additional study:
Abstract #37, 8-5:30pm EDT, Wednesday, April 17th: Utility of Urinary Exosomes/Microvesicles to Non-Invasively Analyze Gene Expression in Prostate Cancer
L.M. Russo, A.N. Scott, P. Motamedinia, K.L. Bate, N. Sadeghi, G. Salazar, M. Lipsky, J. Lin, G. Hruby, K.K. Badani, D.P Petrylak, J.M McKiernan
About Exosome Diagnostics
Exosome Diagnostics is a leading developer of biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes are packaged and shed into all biofluids, including blood, urine and CSF, providing a stable source for intact, cell-specific nucleic acids. The Company's proprietary exosome technology makes use of the presence and natural stability of RNA in exosomes to detect and measure levels of genes responsible for cancer and other diseases. The Company is commercializing exosome technology products for use in both the life sciences and clinical settings. For more information, please visit www.exosomedx.com.
Chief Executive Officer
Exosome Media Contact:
Robert Flamm, Ph.D.
SOURCE Exosome Diagnostics